Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) Operating Expenses (2022 - 2025)

Atara Biotherapeutics' Operating Expenses history spans 4 years, with the latest figure at $4.2 million for Q4 2025.

  • For Q4 2025, Operating Expenses fell 90.75% year-over-year to $4.2 million; the TTM value through Dec 2025 reached $84.9 million, down 60.02%, while the annual FY2025 figure was $84.9 million, 60.02% down from the prior year.
  • Operating Expenses reached $4.2 million in Q4 2025 per ATRA's latest filing, down from $7.0 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $95.5 million in Q1 2022 to a low of $4.2 million in Q4 2025.
  • Average Operating Expenses over 4 years is $57.9 million, with a median of $63.1 million recorded in 2023.
  • The largest YoY upside for Operating Expenses was 1.27% in 2025 against a maximum downside of 90.75% in 2025.
  • A 4-year view of Operating Expenses shows it stood at $75.8 million in 2022, then dropped by 15.24% to $64.2 million in 2023, then dropped by 29.99% to $45.0 million in 2024, then crashed by 90.75% to $4.2 million in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Operating Expenses are $4.2 million (Q4 2025), $7.0 million (Q3 2025), and $14.4 million (Q2 2025).